SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, California..

圣地亚哥-（商业线）-Capstan Therapeutics，Inc.（“Capstan”），一家生物技术公司，致力于通过利用靶向脂质纳米粒子（tLNP）的RNA递送促进细胞的体内重编程，今天宣布，它将提供临床前数据，显示通过tLNP给药在人源化小鼠中快速且稳健的抗肿瘤和抗原代B细胞活性，在癌症免疫治疗学会提供编码抗CD19嵌合抗原受体（CAR）的mRNA。（SITC）在加利福尼亚州圣地亚哥举行的第38届年会。。

“These data highlight the potential for Capstan’s targeted LNP-mRNA platform to provide a truly disruptive, off-the-shelf, cell-free, scalable and tunable solution for patients without the need for harsh lymphodepletion conditioning or viral vectors that are required for conventional ex vivo cell therapies,” said Adrian Bot, M.D., Ph.D., Capstan’s Chief Scientific Officer, and Executive Vice President of R&D.

“这些数据突出表明，Capstan的靶向LNP mRNA平台有可能为患者提供一种真正具有破坏性、现成、无细胞、可扩展和可调的解决方案，而不需要传统的体外细胞疗法所需的苛刻的淋巴消耗条件或病毒载体，”Capstan首席科学官Adrian Bot博士说，和研发的执行副总裁。

“We have demonstrated efficient and therapeutically relevant delivery of mRNA CAR payloads to human T cells. This resulted in rapid and profound pharmacodynamic effect in two mouse models, comprising eradication of human primary B cells or Nalm6 leukemic cells, respectively. These data provide a springboard for developing novel, in vivo CAR therapies that may overcome access and clinical performance issues with currently available ex vivo CAR therapies, with broad applicability in autoimmune and oncology indications.”.

“我们已经证明有效和治疗相关的mRNA CAR有效载荷传递给人类T细胞，这导致了两种小鼠模型的快速和深远的药效学效应，分别包括根除人类原代B细胞或Nalm6白血病细胞，这些数据提供了一个跳板用于开发可以克服获取和临床表现的新型体内CAR疗法目前可用的离体CAR疗法存在问题，广泛适用于自身免疫和肿瘤学适应症“。

Poster Details:

海报细节：

Title: In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology

题目：使用新型靶向LNP mRNA技术对CAR T细胞进行体内工程

Presentation type: Poster

演示类型：海报

Session: Poster Hall

会议：海报厅

Date and time: Saturday, November 4, 2023: 9:00 AM – 8:30 PM

Date and time: Saturday, November 4, 2023: 9:00 AM – 8:30 PM

Lead authors: Gregor Adams, Ph.D., and Haig Aghajanian, Ph.D.

主要作者：Gregor Adams博士和Haig Aghajanian博士。

A copy of the poster will be added to the “Publications and News” section of Capstan’s website at www.capstantx.com/.

海报的副本将添加到Capstan网站www.capstantx.com/的“出版物和新闻”部分。

About Capstan Therapeutics (www.capstantx.com)

关于Capstan Therapeutics（www.capstantx.com）

Capstan Therapeutics, Inc. is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody.

Capstan Therapeutics，Inc.是一家生物技术公司，其使命是通过开发靶向体内RNA技术来为患者增加治疗可能性。核心平台技术包括专有的靶向脂质纳米颗粒（TLNP），其由与重组蛋白质结合剂缀合的LNP组成，例如单克隆抗体。

tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

TLNP旨在提供有效载荷，包括mRNA或基因编辑工具，能够在体内重编程特定的细胞类型。平台技术有可能产生转化疗法，可能应用于广泛的疾病领域，包括自身免疫性疾病，肿瘤学，纤维化和单基因血液疾病。

For more information, please visit www.capstantx.com and follow us on LinkedIn..

欲了解更多信息，请访问www.capstantx.com并在LinkedIn上关注我们。。